Animal research is an important stage in the development of potential cancer therapies. After researchers identify interesting biological effects in laboratory models, studies in animals can help investigate whether those effects can also be observed in a living system. Fenbendazole has attracted attention in this area because several preclinical investigations have reported biological findings that support continued research into its potential anticancer properties.
Read the 2024 review on PubMed →
How Did Animal Research Begin?
Some of the interest in fenbendazole came from an unexpected observation during an animal experiment. Researchers studying lymphoma in mice noticed that tumors did not develop as expected in animals receiving fenbendazole-containing food together with vitamin supplementation. This observation led scientists to investigate the phenomenon more systematically.
Follow-up experiments suggested that the fenbendazole-containing treatment was associated with inhibition of tumor growth in the experimental lymphoma model. The researchers proposed that the observation deserved additional investigation because fenbendazole was already known to interact with cellular structures such as microtubules.
Read the lymphoma study on PMC →
Tumor-Growth Inhibition in Experimental Models
One of the most important questions in animal cancer research is whether a potential compound can influence the growth of an established tumor. Some fenbendazole studies have reported encouraging findings in experimental tumor models.
In the lymphoma research, fenbendazole-containing treatment was associated with reduced tumor development and growth. Although the exact biological explanation was not fully established, the findings provided an early indication that the compound might have effects extending beyond its established antiparasitic activity.
View the experimental lymphoma research →
Research in Cervical Cancer Models
More recent research has expanded the investigation of fenbendazole into other cancer models. A 2025 study examined fenbendazole in cervical cancer models after researchers observed activity against cervical cancer cells and cancer stem-cell populations in laboratory experiments.
The researchers subsequently used mouse xenograft models to investigate tumor growth in vivo. Fenbendazole treatment was associated with suppression of tumor growth in these experimental models, providing additional preclinical evidence supporting further investigation.
Read the 2025 cervical cancer study on PubMed →
Cancer Stem Cells: An Additional Area of Interest
Cancer stem cells are a population of cells that researchers study because they may contribute to tumor development, recurrence, and resistance to some treatments. Targeting these cells is therefore an active area of cancer research.
In the cervical cancer study, researchers investigated fenbendazole’s effects on both conventional cancer cells and cancer stem-cell populations. Their laboratory findings showed reduced proliferation and increased cell death, while the animal experiments provided evidence of tumor-growth suppression.
These observations make cancer stem-cell biology another area where fenbendazole may warrant further experimental investigation.
View the cervical cancer research on PubMed →
Possible Connection With Cellular Metabolism
Another interesting aspect of fenbendazole research is its potential effect on cancer-cell metabolism. Cancer cells frequently undergo metabolic changes that help support rapid growth and survival.
Experimental research has suggested that fenbendazole may interfere with processes involved in glucose utilization and energy metabolism. These findings have led researchers to investigate whether metabolic stress could contribute to the effects observed in cancer models.
Although much of the detailed metabolic evidence comes from laboratory studies rather than animal experiments, the findings provide a biological framework for understanding why researchers continue to examine fenbendazole in vivo.
Read the related research on PubMed →
Microtubules and Cell Division
Microtubules are essential cellular structures involved in chromosome movement and cell division. Because rapidly dividing cancer cells depend on accurate cell division, microtubules are already an established target of several cancer medicines.
Fenbendazole belongs to the benzimidazole class, which can interfere with microtubule-related processes. Experimental research has shown that fenbendazole can affect mammalian tubulin and cellular division pathways.
This provides a possible mechanistic explanation for some of the growth-inhibitory effects investigated in animal cancer models.
View the relevant PubMed research →
Effects on Cancer-Cell Survival
Preclinical research has also examined whether fenbendazole can influence pathways involved in cancer-cell survival and programmed cell death. Experimental findings have included changes in apoptosis, cell-cycle progression, oxidative stress, and mitochondrial activity.
These effects are scientifically interesting because cancer development involves an imbalance between cellular growth and cell death. A compound that influences several interconnected processes may therefore warrant investigation as part of drug-repurposing research.
Read the 2024 review on PubMed →
Why Xenograft Models Matter
Some fenbendazole research uses xenograft models, in which human cancer cells are implanted into laboratory animals. These models allow researchers to observe tumor behavior in a living organism rather than studying isolated cells alone.
When a compound produces an effect in a xenograft model, researchers gain additional information about how the cancer cells respond within a more complex biological environment. The cervical cancer study, for example, used mouse xenograft models to investigate whether the effects observed in laboratory experiments could also influence tumor growth in vivo.
View the cervical cancer xenograft study →
Why Multiple Mechanisms Matter
The potential interest in fenbendazole does not depend on a single proposed mechanism. Research has explored effects involving microtubules, cell-cycle regulation, glucose metabolism, oxidative stress, mitochondrial function, and cell-death pathways.
These biological systems are interconnected. Changes in one pathway can influence others, which is why researchers are interested in understanding the overall cellular response rather than focusing on only one mechanism.
A 2024 review summarized the available research and described several proposed mechanisms that could explain fenbendazole’s experimental anticancer activity.
Read the 2024 review on PubMed →
What Makes the Positive Findings Interesting?
The most interesting aspect of the positive animal research is that some experiments have moved beyond isolated cancer cells and reported tumor-related effects in living animals. Findings such as tumor-growth suppression provide researchers with a reason to continue investigating the compound and its biological mechanisms.
The cervical cancer xenograft findings are particularly relevant because they followed earlier laboratory observations and demonstrated an effect in an animal tumor model. Such progression — from laboratory observation to an in-vivo experiment — is an important part of the preclinical research process.
Read the cervical cancer study on PubMed →
Important Context
These findings are preclinical. Results observed in cells or laboratory animals do not establish that fenbendazole is an effective or safe cancer treatment in humans. Further research, including appropriately designed clinical studies, is necessary to determine whether the effects observed in experimental models translate to human cancer treatment.